Advances in surgical treatment of hepatic metastasis of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2020.04.014

Abstract

Abstract:

In recent years, the treatment of colorectal cancer liver metastasis (CRLM) has been updating, and surgery has become a major cure for CRLM patients. The minimally invasive technique of CRLM, represented by laparoscopy, has certain advantages over traditional open surgery. For specific patients, the use of neoadjuvant chemotherapy, especially for patients with high-risk recurrence factors, has potential application value. However, there is still no effective evidence-based medical evidence to support the clinical treatment of liver metastases from colorectal cancer. Therefore, the treatment of liver metastases from colorectal cancer is still in the process of continuous exploration and requires high-level evidence-based medical evidence to support it. For each patient with liver metastases from colorectal cancer, a multidisciplinary team discussion (MDT) is required to develop an individualized comprehensive treatment plan.

Key words: Colorectal neoplasms, Laparoscope, Colorectal cacer liver metastases, Surgical treatment, Neoadjuvant therapy, Multidisciplinary teamwork

Feng Wang, Liuhua Wang, Jiajie Zhou, Daorong Wang. Advances in surgical treatment of hepatic metastasis of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(04): 408-411.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.04.014

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I04/408

References 34

[1]	Tuo JY, Zhang M, Zheng RS, et al. Report of incidence and mortality of gallbladder cancer in China, 2014[J]. Chin J Oncol, 2018, 40(12): 894-899.
[2]	Kaser SA, Mattiello D, Maurer CA. Distant metastasis in colorectal cancer is a risk factor for anastomotic leakage[J].Annals of Surgical Oncology, 2016, 23(3): 888-893.
[3]	Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases[J]. Cochrane Database Syst Rev, 2008(2): Cd006039.
[4]	Mayo SC, Pulitano C, Marques H, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis[J]. Journal of the American College of Surgeons, 2013, 216(4): 707-716, discussion 16-18.
[5]	中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组中国抗癌协会大肠癌专业委员会,等. 结直肠癌肝转移诊断和综合治疗指南（V2018）[J].中华胃肠外科杂志, 2018, 21(6): 601-626.
[6]	Chua TC, Saxena A, Liauw W, et al. Hepatectomy and resection of concomitant extrahepatic disease for colorectal liver metastases-a systematic review[J]. Euro J Cancer (Oxford, England: 1990), 2012, 48(12): 1757-1765.
[7]	Pulitano C, Bodingbauer M, Aldrighetti L, et al. Colorectal liver metastasis in the setting of lymph node metastasis: defining the benefit of surgical resection[J]. Ann Surg Oncol, 2012, 19(2): 435-442.
[8]	Fukami Y, Kaneoka Y, Maeda A, et al. Simultaneous resection for colorectal cancer and synchronous liver metastases[J]. Surgery Today, 2016, 46(2): 176-182.
[9]	Reddy SK, Pawlik TM, Zorzi D, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis[J]. Ann Surg Oncol, 2007, 14(12): 3481-3491.
[10]	Capussotti L, Ferrero A, Vigano L, et al. Major liver resections synchronous with colorectal surgery[J]. Ann Surg Oncol, 2007, 14(1): 195-201.
[11]	Yin Z, Liu C, Chen Y, et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed?[J]. Hepatology (Baltimore, Md), 2013, 57(6): 2346-2357.
[12]	Gavriilidis P, Sutcliffe RP, Hodson J, et al. Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis[J]. HPB: the Official Journal of the International Hepato Pancreato Biliary Association, 2018, 20(1): 11-19.
[13]	Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival[J]. Ann Surg, 2004, 240(4): 644-657, discussion 57-58.
[14]	Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus[J]. The Oncologist, 2012, 17(10): 1225-1239.
[15]	Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial[J]. Lancet (London, England), 2008, 371(9617): 1007-1016.
[16]	Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3): 309-318, discussion 18-21.
[17]	Ayez N, van der Stok EP, Grunhagen DJ, et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator[J]. Europ J Surg Oncol: the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, 41(7): 859-867.
[18]	Liu W, Zhou JG, Sun Y, et al. The role of neoadjuvant chemotherapy for resectable colorectal liver metastases: a systematic review and meta-analysis[J]. Oncotarget, 2016, 7(24): 37277-37287.
[19]	Cui CH, Huang SX, Qi J, et al. Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis[J]. Oncotarget, 2015, 6(41): 44005-44018.
[20]	Uetake H, Yasuno M, Ishiguro M, et al. A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808)[J]. Ann Surg Oncol, 2015, 22(3): 908-915.
[21]	Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases[J]. J Clin Oncol: Official Journal of the American Society of Clinical Oncology, 2013, 31(16): 1931-1938.
[22]	Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial[J]. The Lancet Oncology, 2014, 15(6): 601-611.
[23]	Wang L, Sun Y, Zhao B, et al. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis[J]. Oncotarget, 2016, 7(34): 55732-55740.
[24]	Imai K, Allard MA, Benitez CC, et al. Early recurrence after hepatectomy for colorectal liver metastases: What optimal definition and what predictive factors?[J]. The Oncologist, 2016, 21(7): 887-894.
[25]	Takorov I, Belev N, Lukanova T, et al. Laparoscopic combined colorectal and liver resections for primary colorectal cancer with synchronous liver metastases[J]. Annals of Hepato-Biliary-Pancreatic Surgery, 2016, 20(4): 167-172.
[26]	Xu X, Guo Y, Chen G, et al. Laparoscopic resections of colorectal cancer and synchronous liver metastases: a case controlled study[J]. Minimally Invasive Therapy & Allied Technologies: MITAT: Official Journal of the Society for Minimally Invasive Therapy, 2018, 27(4): 209-216.
[27]	Abu Hilal M, Underwood T, Zuccaro M, et al. Short- and medium-term results of totally laparoscopic resection for colorectal liver metastases[J]. Bri J Surg, 2010, 97(6): 927-933.
[28]	Nguyen KT, Laurent A, Dagher I, et al. Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes[J]. Ann Surg, 2009, 250(5): 842-848.
[29]	Yue M, Li S, Yan G, et al. Short- and long-term outcomes of laparoscopic hepatectomy for colorectal liver metastases in elderly patients[J]. Cancer Management and Research, 2018, 10: 2581-2587.
[30]	Chen YW, Huang MT, Chang TC. Long term outcomes of simultaneous laparoscopic versus open resection for colorectal cancer with synchronous liver metastases[J]. Asian Journal of Surgery, 2019, 42(1): 217-223.
[31]	Silberhumer GR, Paty PB, Denton B, et al. Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer[J]. Surgery, 2016, 160(1): 67-73.
[32]	Moris D, Tsilimigras DI, Machairas N, et al. Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review[J]. J Surg Oncol, 2019, 119(1): 30-39.
[33]	Gomez Dorronsoro ML, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy[J]. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2014, 16(3): 234-242.
[34]	Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement[J]. Current Oncology (Toronto, Ont), 2014, 21(1): e129-136.

Please choose a citation manager

Content to export